课题基金 / 基金详情

DEFINING THE HCV INFECTIOUS WINDOW PERIOD IN THE CHIMPANZEE

DEFINING THE HCV INFECTIOUS WINDOW PERIOD IN THE CHIMPANZEE
黑猩猩 HCV 感染窗口期的定义
批准号:
7562417
负责人:
KRISHNA H MURTHY
金额:
$2.8万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-05-01 至 2008-04-30

项目摘要

项目成果

KRISHNA H MURTHY的其他基金

相似基金

相关文献

中文摘要
翻译
这个子项目是众多研究子项目之一
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The infectious window period for hepatitis C virus (HCV), the time between exposure to the virus and the first detection of viral RNA, is not well defined. By establishing the window period, the risk of transmission of HCV by blood products can be further reduced and or prevented. The objective is to define and characterize the infectious window period for HCV in the chimpanzee model. Two chimpanzees have been selected and baseline liver enzyme levels have been determined. HCV borderline positive and negative plasma panels are being put together for the proposed studies. One chimpanzee was IV infused with 50 ml of plasma from each of five individual donors from a panel negative for HCV by nucleic acid testing (NAT). The animals become infected indicating that HCV was present below the level of detection of NAT. Additional virological and immunological assays are being performed at the represent time. Virological assays indicated that the animal rapidly cleared the infection and did not seroconvert. The planned inoculation of the second animal is on hold until a final decision is made on using a different plasma panel.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CHIMPANZEES FOR HEPATITIS OR AIDS RESEARCH
IMMUNOGENICITY OF HIV CANDIDATE VACCINES IN BABOONS
NEOANTIGENICITY OF RIBOFLAVIN AND LIGHT TREATED RBCS IN BABOONS
DEVELOPMENT OF HEPATITIS C VIRUS-LIKE PARTICLES AS CANDIDATE HCV VACCINE
海外基金